DK3143027T3 - Ny solvatiseret krystalform af rifaximin, fremstilling, sammensætninger og anvendelser heraf - Google Patents

Ny solvatiseret krystalform af rifaximin, fremstilling, sammensætninger og anvendelser heraf Download PDF

Info

Publication number: DK3143027T3
Authority: DK; Denmark
Prior art keywords: rifaximin; compositions; applications; preparation; crystal form
Prior art date: 2014-05-12

Application number

DK15726344.3T

Other languages

English (en)

Inventor

Giuseppe Claudio Viscomi

Paola Maffei

Annalisa Sforzini

Fabrizia Grepioni

Laura Chelazzi

Original Assignee

Alfasigma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-12

Filing date

2015-05-07

Publication date

2019-08-12

2015-05-07 Application filed by Alfasigma Spa filed Critical Alfasigma Spa

2019-08-12 Application granted granted Critical

2019-08-12 Publication of DK3143027T3 publication Critical patent/DK3143027T3/da

Links

239000000203 mixture Substances 0.000 title 1
NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 title 1
229960003040 rifaximin Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)

DK15726344.3T 2014-05-12 2015-05-07 Ny solvatiseret krystalform af rifaximin, fremstilling, sammensætninger og anvendelser heraf DK3143027T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461992017P	2014-05-12	2014-05-12
PCT/IB2015/053342 WO2015173697A1 (en)	2014-05-12	2015-05-07	New solvated crystal form of rifaximin, production, compositions and uses thereof

Publications (1)

Publication Number	Publication Date
DK3143027T3 true DK3143027T3 (da)	2019-08-12

Family

ID=53276210

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK19169546.9T DK3546464T3 (da)	2014-05-12	2015-05-07	Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme
DK15726344.3T DK3143027T3 (da)	2014-05-12	2015-05-07	Ny solvatiseret krystalform af rifaximin, fremstilling, sammensætninger og anvendelser heraf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK19169546.9T DK3546464T3 (da)	2014-05-12	2015-05-07	Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme

Country Status (17)

Country	Link
US (2)	US9938298B2 (da)
EP (2)	EP3143027B1 (da)
JP (1)	JP6576953B2 (da)
KR (1)	KR102362719B1 (da)
AU (1)	AU2015260837B2 (da)
CA (1)	CA2940601C (da)
DK (2)	DK3546464T3 (da)
EA (1)	EA030457B1 (da)
ES (2)	ES2810010T3 (da)
HR (2)	HRP20191520T1 (da)
HU (2)	HUE044748T2 (da)
NZ (1)	NZ723571A (da)
PL (2)	PL3546464T3 (da)
PT (2)	PT3143027T (da)
RS (2)	RS60576B1 (da)
SI (2)	SI3143027T1 (da)
WO (1)	WO2015173697A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI335218B (en) *	2003-02-19	2011-01-01	Panion & Bf Biotech Inc	Ferric organic compounds, uses thereof and methods of making same
PT1698630E (pt)	2005-03-03	2014-09-15	Alfa Wassermann Spa	Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ES2621557T3 (es)	2014-03-31	2017-07-04	Euticals S.P.A.	Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
DK3546464T3 (da)	2014-05-12	2020-07-27	Alfasigma Spa	Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme
JP7811085B2 (ja)	2017-09-01	2026-02-04	ピーティーシーセラピューティクスエムピー，インコーポレイテッド	セピアプテリンを含む医薬組成物及びその使用
EP3846784B1 (en)	2018-09-06	2026-04-22	Fachhochschule Nordwestschweiz	Controlled drug release formulation
WO2020208140A1 (en)	2019-04-12	2020-10-15	Sandoz Ag	Rifaximin-containing granules
GR1010652B (el) *	2023-04-20	2024-03-12	Φαρματεν Α.Β.Ε.Ε.,	Φαρμακευτικο σκευασμα που περιλαμβανει εναν αντιμικροβιακο παραγοντα και μεθοδος για την παρασκευη αυτου
WO2025170483A1 (ru) *	2024-02-07	2025-08-14	Общество с ограниченной ответственностью "БИННОФАРМ ГРУПП"	Фармацевтическая композиция, обладающая антибиотической активностью

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1154655B (it)	1980-05-22	1987-01-21	Alfa Farmaceutici Spa	Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1215976A (en)	1984-05-15	1986-12-30	Vincenzo Cannata	New process for the synthesis of imidazo rifamycins
IT1199374B (it)	1984-05-15	1988-12-30	Alfa Farmaceutici Spa	Processo per la preparazione di pirido-imidazo-rifamicine
IT1199413B (it)	1984-09-26	1988-12-30	Alfa Farmaceutici Spa	Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en)	1986-08-28	1994-10-18	Enzacor Properties Limited	Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
US5443826A (en)	1988-08-02	1995-08-22	Borody; Thomas J.	Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
IT1253711B (it)	1991-12-17	1995-08-23	Alfa Wassermann Spa	Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it)	1993-03-23	1996-09-24	Alfa Wassermann Spa	Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US6861053B1 (en)	1999-08-11	2005-03-01	Cedars-Sinai Medical Center	Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5840332A (en)	1996-01-18	1998-11-24	Perio Products Ltd.	Gastrointestinal drug delivery system
EP2060183A3 (en)	1996-10-16	2009-06-03	Napo Pharmaceuticals, Inc.	Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
IT1290679B1 (it)	1997-02-14	1998-12-10	Alfa Wassermann Spa	Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US6770623B1 (en)	1997-12-09	2004-08-03	Eli Lilly And Company	Stabilized teriparatide solutions
US20030059471A1 (en)	1997-12-15	2003-03-27	Compton Bruce Jon	Oral delivery formulation
US20030157174A1 (en)	2000-03-23	2003-08-21	Takayuki Tsukuda	Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
DE10045547A1 (de)	2000-09-14	2002-04-04	Infineon Technologies Ag	Verfahren zur systemunabhängigen digitalen Erzeugung von Mobilkommunikations-Sendesignalen verschiedener Mobilfunkstandards
US8101209B2 (en)	2001-10-09	2012-01-24	Flamel Technologies	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20080262024A1 (en)	2003-11-07	2008-10-23	Giuseppe Claudio Viscomi	Rifaximin compositions and method of use
US7923553B2 (en)	2003-11-07	2011-04-12	Alfa Wassermann, S.P.A.	Processes for the production of polymorphic forms of rifaximin
ITMI20032144A1 (it)	2003-11-07	2005-05-08	Alfa Wassermann Spa	Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en)	2004-11-04	2011-03-15	Alfa Wassermann, S.P.A.	Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en)	2003-11-07	2011-03-08	Alfa Wassermann, S.P.A.	Polymorphic forms α, β and γ of rifaximin
US20050196418A1 (en)	2004-03-04	2005-09-08	Yu Ruey J.	Bioavailability and improved delivery of alkaline pharmaceutical drugs
SE528938C2 (sv)	2005-02-08	2007-03-20	Ortic Ab	Hydroformningsenhet
US8003118B2 (en)	2005-03-02	2011-08-23	Kodsi Robert E	Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210492A1 (en)	2005-03-02	2006-09-21	Kodsi Robert E	Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en)	2005-03-02	2006-09-21	Kodsi Robert E	Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
PT1698630E (pt)	2005-03-03	2014-09-15	Alfa Wassermann Spa	Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it)	2005-03-07	2005-06-06	Alfa Wassermann Spa	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it)	2006-09-05	2008-03-06	Alfa Wassermann Spa	Uso di polioli per ottenere forme polimorfe stabili di rifaximina
WO2008035109A1 (en)	2006-09-22	2008-03-27	Cipla Limited	Rifaximin
ITMI20071241A1 (it)	2007-06-20	2008-12-21	Solmag S P A	Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (en)	2007-07-06	2009-01-15	Lupin Limited	Pharmaceutical compositions of rifaximin
PL2011486T5 (pl)	2007-07-06	2016-09-30	Lupin Ltd	Farmaceutyczne kompozycje rifaksyminy
WO2009008006A2 (en)	2007-07-06	2009-01-15	Lupin Limited	Pharmaceutical compositions for gastrointestinal drug delivery
US7709634B2 (en)	2007-09-20	2010-05-04	Apotex Pharmachem Inc.	Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja)	2007-10-10	2011-01-06	ルピン・リミテッド	胃腸障害を処置するための医薬用組み合わせおよび組成物
GEP20135898B (en)	2008-02-25	2013-08-12	Salix Pharmaceuticals Ltd	Rifaximin forms and usage
US8486956B2 (en)	2008-02-25	2013-07-16	Salix Pharmaceuticals, Ltd	Forms of rifaximin and uses thereof
BRPI0908026B8 (pt)	2008-02-26	2021-05-25	Salix Pharmaceuticals Ltd	uso de rifaximina no tratamento de doenças do intestino
US20110035232A1 (en)	2008-10-02	2011-02-10	Salix Pharmaceuticals, Ltd.	Methods of treating hepatic encephalopathy
HRP20200284T1 (hr)	2008-10-02	2020-07-10	Salix Pharmaceuticals, Ltd.	Postupci liječenja hepatičke encefalopatije
US7928115B2 (en)	2008-10-02	2011-04-19	Salix Pharmaceuticals, Ltd.	Methods of treating travelers diarrhea and hepatic encephalopathy
WO2010044093A1 (en)	2008-10-16	2010-04-22	Strides Arcolab Limited	Formulations containing rifaximin
KR101906177B1 (ko)	2008-12-10	2018-10-10	시플라 리미티드	리팍시민 복합체
IT1397617B1 (it) *	2009-04-20	2013-01-18	Alfa Wassermann Spa	Nuovi derivati della rifamicina
US8772242B2 (en)	2009-10-26	2014-07-08	Thomas Julius Borody	Therapy for enteric infections
GEP201706693B (en)	2009-10-27	2017-07-10	Lupin Ltd	Solid dispersion of rifaximin
WO2011061748A1 (en)	2009-11-19	2011-05-26	Strides Arcolab Limited	Rifaximin premix
CA2781580A1 (en)	2009-11-23	2011-05-26	Cipla Limited	Topical foam composition
CN102724961A (zh)	2009-11-23	2012-10-10	希普拉有限公司	局部泡沫组合物
EP2401282B2 (en)	2009-12-28	2017-01-04	Silvio Massimo Lavagna	Method for the production of amorphous rifaximin
CN101773465B (zh)	2010-01-19	2012-11-07	南京泛太化工医药研究所	以氨基酸为稳定剂的聚合物胶束载药系统
EP2544660B1 (en)	2010-03-10	2018-06-13	Lupin Limited	Rifaximin ready-to-use suspension
MX2012013945A (es)	2010-06-03	2013-05-06	Salix Pharmaceuticals Ltd	Nuevas formas de rifaximina y usos de las mismas.
CA2802874A1 (en)	2010-06-16	2011-12-22	Apotex Pharmachem Inc.	Polymorphic forms of rifaximin
PH12013500082B1 (en)	2010-07-12	2019-06-28	Salix Pharmaceuticals Ltd	Formulations of rifaximin and uses thereof
CN103221032A (zh)	2010-09-13	2013-07-24	西普拉有限公司	药物组合物
IT1403847B1 (it)	2010-09-22	2013-11-08	Alfa Wassermann Spa	Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es)	2010-11-05	2012-05-10	Interquim, S.A. De C.V.	Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en)	2010-12-09	2012-06-14	Cipla Limited	Suppositories comprising rifaximin
MX350448B (es)	2011-02-11	2017-09-07	Salix Pharmaceuticals Ltd	Formas de rifaximina y usos de las mismas.
EP2705042A1 (en)	2011-05-02	2014-03-12	Ranbaxy Laboratories Limited	Rifaximin dimethylformamide solvate
ITMI20110890A1 (it)	2011-05-19	2012-11-20	A M S A Anonima Materie Sint & Affini S P A	Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (en)	2011-05-19	2012-11-22	Friulchem Spa	New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITBO20110461A1 (it)	2011-07-29	2013-01-30	Alfa Wassermann Spa	Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
JP2013184902A (ja) *	2012-03-06	2013-09-19	Aska Pharmaceutical Co Ltd	リファキシミン含有結晶
CA2876737A1 (en)	2012-06-13	2013-12-19	Apotex Pharmachem Inc.	Polymorphic forms of rifaximin
ITBO20120368A1 (it)	2012-07-06	2014-01-07	Alfa Wassermann Spa	Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en)	2012-12-12	2017-12-26	Sun Pharmaceutical Industries Limited	Pharmaceutical compositions of rifaximin
EA032705B1 (ru)	2013-04-12	2019-07-31	Альфасигма С.П.А.	Способ лечения или предупреждения энтеропатии
JP2016526032A (ja)	2013-05-17	2016-09-01	サリックスファーマスーティカルズ，インコーポレーテッド	ポジション（ｐｏｓｉｔｉｏｎ）放射断層撮影（ｐｅｔ）スキャンでリファキシミンを使用する方法
US9018225B1 (en)	2013-07-26	2015-04-28	Novel Laboratories	Rifaximin crystalline forms and methods of preparation thereof
ITMI20131307A1 (it)	2013-08-02	2015-02-02	A M S A Anonima Materie Sint & Affini S P A	Processo per la preparazione di refaximina k
ES2621557T3 (es)	2014-03-31	2017-07-04	Euticals S.P.A.	Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
EP3134415A4 (en)	2014-04-19	2017-10-25	Granules India Limited	An improved process for the preparation of rifamycin derivatives
DK3546464T3 (da)	2014-05-12	2020-07-27	Alfasigma Spa	Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme
WO2016063289A2 (en)	2014-10-22	2016-04-28	Strides Arcolab Limited	Pharmaceutical tablet compositions comprising rifaximin
WO2017021975A1 (en)	2015-08-06	2017-02-09	Msn Laboratories Private Limited	Process for the preparation of crystalline forms of rifaximin
TR201816080T4 (tr)	2016-03-24	2018-11-21	Sandoz Ag	Ri̇faksi̇mi̇n alfa & delta i̇çeren farmasöti̇k bi̇leşi̇m
EP3536311B1 (en)	2016-03-24	2021-12-22	Sandoz AG	Storage stable composition comprising rifaximin alpha
US9988398B2 (en)	2016-06-07	2018-06-05	Cadila Healthcare Limited	Crystalline form of rifaximin and process for its preparation
WO2018158646A1 (en)	2017-03-02	2018-09-07	Granules India Limited	Rifaximin crystalline form
WO2018178777A1 (en)	2017-03-31	2018-10-04	Granules India Limited	Process for the preparation of rifaximin crystalline form
EP3416627B9 (en)	2017-04-26	2020-04-22	Sandoz AG	Oral dosage form comprising rifaximin in form beta

2015
- 2015-05-07 DK DK19169546.9T patent/DK3546464T3/da active
- 2015-05-07 ES ES19169546T patent/ES2810010T3/es active Active
- 2015-05-07 PL PL19169546T patent/PL3546464T3/pl unknown
- 2015-05-07 HU HUE15726344 patent/HUE044748T2/hu unknown
- 2015-05-07 PL PL15726344T patent/PL3143027T3/pl unknown
- 2015-05-07 HU HUE19169546A patent/HUE050054T2/hu unknown
- 2015-05-07 WO PCT/IB2015/053342 patent/WO2015173697A1/en not_active Ceased
- 2015-05-07 RS RS20200857A patent/RS60576B1/sr unknown
- 2015-05-07 NZ NZ723571A patent/NZ723571A/en unknown
- 2015-05-07 PT PT15726344T patent/PT3143027T/pt unknown
- 2015-05-07 EA EA201692110A patent/EA030457B1/ru unknown
- 2015-05-07 RS RSP20191133 patent/RS59250B1/sr unknown
- 2015-05-07 CA CA2940601A patent/CA2940601C/en active Active
- 2015-05-07 ES ES15726344T patent/ES2742106T3/es active Active
- 2015-05-07 EP EP15726344.3A patent/EP3143027B1/en active Active
- 2015-05-07 JP JP2016566935A patent/JP6576953B2/ja active Active
- 2015-05-07 KR KR1020167031391A patent/KR102362719B1/ko active Active
- 2015-05-07 SI SI201530871T patent/SI3143027T1/sl unknown
- 2015-05-07 HR HRP20191520 patent/HRP20191520T1/hr unknown
- 2015-05-07 PT PT191695469T patent/PT3546464T/pt unknown
- 2015-05-07 EP EP19169546.9A patent/EP3546464B1/en active Active
- 2015-05-07 US US15/310,436 patent/US9938298B2/en active Active
- 2015-05-07 SI SI201531304T patent/SI3546464T1/sl unknown
- 2015-05-07 AU AU2015260837A patent/AU2015260837B2/en active Active
- 2015-05-07 DK DK15726344.3T patent/DK3143027T3/da active
2018
- 2018-02-27 US US15/907,117 patent/US10428086B2/en active Active
2020
- 2020-07-13 HR HRP20201093TT patent/HRP20201093T1/hr unknown

Also Published As

Publication number	Publication date
KR102362719B1 (ko)	2022-02-14
ES2742106T3 (es)	2020-02-13
EP3546464A1 (en)	2019-10-02
AU2015260837B2 (en)	2019-02-28
EP3143027B1 (en)	2019-07-10
WO2015173697A1 (en)	2015-11-19
HUE044748T2 (hu)	2019-11-28
US9938298B2 (en)	2018-04-10
DK3546464T3 (da)	2020-07-27
HUE050054T2 (hu)	2020-11-30
NZ723571A (en)	2020-02-28
CA2940601C (en)	2021-08-24
CA2940601A1 (en)	2015-11-19
JP6576953B2 (ja)	2019-09-18
HRP20191520T1 (hr)	2019-11-29
PL3143027T3 (pl)	2019-11-29
US10428086B2 (en)	2019-10-01
PT3546464T (pt)	2020-08-05
EP3143027A1 (en)	2017-03-22
SI3546464T1 (sl)	2020-09-30
KR20170003568A (ko)	2017-01-09
RS59250B1 (sr)	2019-10-31
EA030457B1 (ru)	2018-08-31
AU2015260837A1 (en)	2016-09-15
US20170088557A1 (en)	2017-03-30
JP2017515821A (ja)	2017-06-15
HRP20201093T1 (hr)	2020-10-30
ES2810010T3 (es)	2021-03-08
PL3546464T3 (pl)	2020-11-02
EA201692110A1 (ru)	2017-05-31
SI3143027T1 (sl)	2019-10-30
RS60576B1 (sr)	2020-08-31
EP3546464B1 (en)	2020-06-17
US20180354971A1 (en)	2018-12-13
PT3143027T (pt)	2019-09-20

Publication	Publication Date	Title
DK3212778T3 (da)	2019-11-04	Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser
DK3144001T3 (da)	2021-11-15	Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3102555T3 (da)	2021-08-09	Sammensætninger af forbindelser og anvendelser deraf
DK3160470T3 (da)	2022-10-24	Analoger af pridopidin, fremstilling og anvendelse heraf
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
PL3407888T3 (pl)	2021-08-30	Związki pirydopirolochinoksaliny, ich kompozycje i zastosowania
DK3557998T3 (da)	2023-11-20	Sammensætninger, kompositioner og anvendelsesmetoder
DK3191421T3 (da)	2020-07-27	Glassammensætninger, glassammensætninger til fremstilling af glasfibre og glasfibre fremstillet deraf
DK3185868T3 (da)	2022-05-23	Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3137169T3 (da)	2022-02-14	Hæmmere af lysin-specifik demethylase-1
DK3170842T3 (da)	2019-10-07	Immunologisk effektorcelle af målrettet cld18a2, fremstillingsfremgangsmåde og anvendelse deraf
DK3143027T3 (da)	2019-08-12	Ny solvatiseret krystalform af rifaximin, fremstilling, sammensætninger og anvendelser heraf
DK2924093T3 (da)	2018-01-29	Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3262008T3 (da)	2021-03-15	Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed
DK3393655T3 (da)	2021-03-15	Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3007695T3 (da)	2024-03-18	Sammensætninger og fremgangsmåder til behandling af anæmi
DK3394259T3 (da)	2024-05-27	Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK3081263T3 (da)	2020-03-16	Sammensætninger og redskaber til behandling af glaukom
DK3331879T3 (da)	2020-08-10	Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3077513T5 (da)	2024-10-14	Sammensætninger og fremgangsmåder til fremstilling af (r)-retikulin og udgangsstoffer deraf
DK3494119T3 (da)	2024-12-02	Forbindelser og sammensætninger og anvendelser deraf
DK3150685T3 (da)	2019-08-12	Oliebaserede sammensætninger til dispergering af asfaltener og paraffiner
DK3164123T3 (da)	2020-08-03	Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
DK3265126T3 (da)	2021-09-13	Kombinationsformulering af tesofensin og metoprolol
DK3183295T3 (da)	2023-08-21	Fraktioneret alkyleret cyclodextrinsammensætning og fremgangsmåder til fremstilling og anvendelse af samme